How should adenosine be administered to a hemodynamically stable patient with supraventricular tachycardia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Administer Adenosine in SVT

Adenosine should be administered as a rapid 6 mg intravenous bolus through a proximal (large-bore) IV line, immediately followed by a 20 mL saline flush, with the patient supine and continuous ECG monitoring. 1, 2

Administration Technique

Standard Dosing Protocol

  • Initial dose: 6 mg IV rapid bolus
  • If unsuccessful: 12 mg IV rapid bolus (may repeat once)
  • Maximum cumulative dose: Up to 12 mg per attempt 1, 3

Critical Technical Points

IV Access and Injection Site:

  • Use a proximal/large-bore peripheral IV (antecubital or higher) 2
  • Avoid distal hand or wrist IVs—adenosine's ultra-short half-life (seconds) means it may be metabolized before reaching the heart if given distally
  • If using a central line, reduce initial dose to 3 mg (77% success rate vs 37% peripherally) 4

Injection Technique:

  • Administer as a rapid bolus push (not slow infusion)
  • Immediately follow with 20 mL normal saline flush using the double-syringe technique
  • Push the saline flush rapidly to propel adenosine into central circulation 1, 2

Patient Positioning:

  • Keep patient supine during administration 1, 2

Essential Monitoring and Safety

Before Administration:

  • Confirm continuous ECG monitoring is in place 2
  • Have electrical cardioversion equipment immediately available (adenosine can precipitate atrial fibrillation with rapid ventricular response or ventricular fibrillation in pre-excited patients) 2
  • Ensure resuscitation equipment is at bedside 1

During/After Administration:

  • Record continuous ECG strip during and after injection to capture:
    • Successful termination vs. failure
    • Immediate reinitiation of tachycardia
    • Unmasking of underlying atrial flutter or atrial tachycardia 2

Expected Outcomes and Timing

Efficacy:

  • 90-95% success rate for AVNRT and orthodromic AVRT 1, 2
  • Average time to conversion: 30 seconds 3
  • First 6 mg dose succeeds in 57-80% of cases 5, 6, 3
  • Cumulative success with 6 mg then 12 mg: 93-94% 3

Common Side Effects (occur in ~30-36% but last <1 minute):

  • Chest discomfort, dyspnea, flushing, throat tightness 2, 3
  • These are expected and brief—warn the patient beforehand

Clinical Algorithm

  1. First-line: Attempt vagal maneuvers (Valsalva, carotid massage) 1, 2

  2. If vagal maneuvers fail:

    • Adenosine 6 mg rapid IV bolus + immediate 20 mL saline flush
    • Wait 1-2 minutes
  3. If no conversion:

    • Adenosine 12 mg rapid IV bolus + immediate 20 mL saline flush
    • May repeat 12 mg dose once if needed
  4. If adenosine fails or contraindicated:

    • Consider IV calcium channel blockers (diltiazem/verapamil) or beta-blockers in stable patients 1
    • Proceed to synchronized cardioversion if unstable or refractory 1, 2

Critical Contraindications and Pitfalls

Absolute Contraindications:

  • Second- or third-degree AV block (without pacemaker)
  • Sick sinus syndrome (without pacemaker)
  • Asthma or bronchospastic lung disease
  • Known hypersensitivity to adenosine 7

Major Pitfall—Pre-excited Atrial Fibrillation:

  • DO NOT give adenosine if you suspect pre-excited AF (irregular wide-complex tachycardia in WPW)
  • Adenosine can precipitate ventricular fibrillation in this setting 2
  • Use synchronized cardioversion or procainamide/ibutilide instead 2

Drug Interactions:

  • Methylxanthines (caffeine, theophylline, aminophylline) antagonize adenosine—may need higher doses 7
  • Dipyridamole and carbamazepine potentiate adenosine—consider lower initial dose (3 mg) 7

Weight-Based Dosing Consideration

Recent evidence suggests weight-based dosing (≥0.1 mg/kg) may improve first-dose success rates without increasing adverse effects 8. However, the 2015 ACC/AHA/HRS guidelines remain the standard with fixed 6 mg and 12 mg doses 1. For patients >120 kg, consider starting with 12 mg if the 6 mg dose fails, rather than repeating 6 mg.

Hemodynamically Unstable Patients

If the patient is hemodynamically unstable (hypotension, altered mental status, shock, acute heart failure):

  • Synchronized cardioversion is first-line 1, 2
  • However, adenosine may be attempted first if immediately available and the patient has not yet deteriorated to cardiovascular collapse 2, 9
  • Recent data suggests adenosine can be safely attempted in unstable SVT before cardioversion, potentially avoiding sedation risks 9

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.